Nice article.
I also took the time to read the comments (something I doubt TA charters would do, all they need is in price and volume formations that serve to foretell the future).
The substance of the article goes to what I have pondered in some of my previous posts . . . the establishment of current big health care providers . . . , hardly will accept new whiz kids inventing and manufacturing novel technology, that threatens their pole position in the health care food chain.
This just might be a factor in why DRIO is not getting rapid FDA Device Approval?
One of the comments mentioned the blood testing technology factor, that a blood glucose readers is based on an electric electrode coated with a specific chemical, as its means of developing a read-out to its visual meter. The test strip (carrying the blood prick
sample placed into the reader device, is a cost factor that Medicare is trying to lessen in its pay-outs. Medicare seems to be forcing out the smaller device and strips companies, and also forcing distributors to focus on fewer patient choice of reader devices (to cut cost pay-outs for Medicare). As a result of trying to achieve cost-cutting efficiency in the Medicare program, innovative new start-ups and their techs will be under super pressure and difficulty in getting into the device/strip supplier stream.
Quality will suffer, in the seeming achievement of quantity of service economizing?
We retail investors may find ourselves unable to 'lite' the funding monies fuse needed to propel DRIO, into new chart highs. And, private placements also will not be able to accomplish the needed R&D and advertising monies either. The political winds of whatever variant, coupled with collapsing worldwide economies threatening,
bode ill for our DRIO success?
I do recommend that DRIO pursue DOD and Public Health Care grant funding to develop those other 'bodily fluids' mobile reader devices tech. The other alternative, for us retail investors to see a profit on our contributions, is to sell the diabetic
reader tech to a larger partner in this field. DRIO can than have the money to undertake demo tech in the other /bodily fluids' reader fields of endeavor?
We might also get lucky and get Emergent Use Approval from FDA in the next say 6-9 months, and this will give our stock price the underpinning PR effect boost it does need.
We have other mobile reader device competitors breathing down our throat, and our timetable window of opportunity is less than 18 months. And, they have much more money, proven talent, and government interest than DRIO has. That $5000 initial unit price Star Trek type universal disease presence reader, that can read hundreds of health and diseases via SW programing, will effectively kill our chances of getting other 'bodily fluids' device reader contracts?
Like E-Cigs . . . we may find DRIO tech can be rather quickly duplicated in Asian production and distribution low-cost bid markets. Due to Free Trade Agreements, such products can enter the USA tariff free and overwhelm small producers like DRIO.
I do not now see any possibility of low volume stock chart evidence, as a future up chart driver for our stock price, without a suitable PR effect propeller.
If $millions of new stock purchases are made (and we have no accompanying PR bomb-shell), which direction would the stock price naturally want to move to?
Our Private Placements investor might just want some profit, and can get it up or down direction?
We are now less than 20 trading days to beginning of new 2015 stock market year (rather doubtful any major PR effect is going to transpire rest of 2014)?
We are all rather living in a trading range box for the next 6-9 months, awaiting news?
AI
